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Introduction
The synthetic cathinone derivative 4-methylmethcathinone (mephedrone) was first synthesized in 1929 and became popular amongst recreational users at the beginning of the 21 st century as a legal high (Green et al., 2014) . Although mephedrone has been implicated in a number of deaths and became illegal in Europe and the United States between 2010 and 2012 (Dargan et al., 2011; Gershman and Fass, 2012) , it remains widely available for illicit use (Elliott and Evans, 2014; Kelly et al., 2013; Yamamoto et al., 2013) and users report similar psychoactive effects to 3,4-methylenedioxymethamphetamine (MDMA). Mephedrone is a high-affinity substrate for the monoamine reuptake transporters for dopamine, noradrenaline and 5-hydroxytrypatamine (5-HT). Once transported into the cell mephedrone stimulates neurotransmitter release and disrupts vesicular storage by interaction with the vesicular monoamine transporter (VMAT) and can also stimulate non-exocytotic release by reversing the monoamine transporter flux (Simmler et al., 2013) . Consistent with this, systemic mephedrone administration to freely moving rats elevates extracellular levels of dopamine, and to a greater extent 5-HT, in the nucleus accumbens (Baumann et al., 2012; Kehr et al., 2011; Wright et al., 2012) .
Multiple re-dosing is common with mephedrone users attempting to maintain the desired effects of this short-acting drug, and while a typical recreational dose is often between 100-200mg, individuals may re-dose and ingest up to 4g in a single session (Schifano et al., 2011; Winstock et al., 2011) . Most studies show the acute effect of a single injection, or self-administration of mephedrone in the rat is hypothermia (Aarde et al., 2013; Miller et al., 2013; Shortall et al., 2013a) , but hyperthermia has also been reported following rapid repeated dosing (Baumann et al, 2012; Hadlock et al, 2011) . Given the established association of hyperthermia with life-threatening adverse effects of MDMA (Docherty and Green, 2010) , it is essential to see if there might be a similar adverse risk with repeated mephedrone. The current study therefore examined the temporal profile of the temperature and locomotor response to short-term repeated mephedrone and established the involvement of serotonergic and dopaminergic neurons in these changes because of their known role in the effects of MDMA.
In the current study rats received three intraperitoneal (i.p.) injections of mephedrone (10mg/kg) at 2h intervals. Previous calculations suggest that this dose and route of mephedrone administration would produce similar plasma exposure to that occurring in many recreational users (Green et al., 2014) . However, as pharmacokinetic studies of mephedrone have not been performed in man and there is wide variation in use of single or repeated recreational dose schedules, firm conclusions of the translatable accuracy of this dose cannot be made. Importantly, 10mg/kg i.p. produces robust but sub-maximal physiological and behavioral changes in the rat (Shortall et al., 2013a; Shortall et al., 2013b; Wright et al., 2012) , thereby enabling detection of either enhanced or attenuated temperature and locomotor effects following repeated injection (Green et al., 2014 ). In the current study, all experiments were performed at ambient temperature as Wright et al, (2012) observed that mephedrone produced a comparable hypothermia and increase in locomotor activity when recorded at normal (23 o C) and elevated (27 o C) ambient room temperature in Wistar rats.
The current repeat dosing studies used continuous radiotelemetry to accurately and repeatedly record locomotor activity and core body temperature over a prolonged period in the same animal, without repeated insertion of a rectal probe, which would confound assessment of activity, at a consistent dose interval to previous preclinical studies using MDMA or mephedrone (Baumann et al., 2012; Baumann et al., 2008; Rodsiri et al., 2011) .
Because mephedrone causes hyperlocomotion (Shortall et al., 2013b) and the striatum plays a role in motor activity (Schultz, 2000) , extracellular dopamine and 5-HT efflux from this region were measured by in vivo microdialysis to examine whether neurotransmitter release correlated with the behavioral effects.
Previous pharmacological studies suggest the involvement of dopamine in mephedrone-induced hypothermia (Shortall et al., 2013a ), so we further examined the contribution of serotonergic and dopaminergic neurons to the behavioral effects of mephedrone. Intracerebroventricular (i.c.v.) pre-treatment with selective neurotoxins (5,7-dihydroxytryptamine (5,7-DHT) and 6-hydroxytryamine, 6-OHDA, respectively) was used to determine the impact of 5-HT or dopamine depletion on the thermoregulatory and locomotor stimulant effects of repeated mephedrone measured using radiotelemetry. After identifying a role of 5-HT in mephedrone-induced hyperactivity and hypothermia, a final acute study investigated the involvement of specific 5-HT receptors by assessing the impact of selective 5-HT 1A, 5-HT 1B or 5-HT 7 receptor antagonists on acute mephedrone-induced hyperlocomotion or hypothermia. These receptors were chosen because of their known role in locomotion and/or thermoregulation in the rat and to permit comparisons with the published effects of MDMA. Radiotelemetry was not used in these studies in accordance with the three Rs principle that invasive surgical implantation was unnecessary for acute measurement. This is the first study to concomitantly examine the effects of repeated mephedrone on hyperactivity, hypothermia and striatal dopamine efflux in short time periods (to provide a good temporal resolution) and establish the differential role of dopamine and 5-HT in mephedrone-induced hyperactivity and hyperthermia for comparison with the established effects of repeated MDMA injection.
Materials and Methods

Animals
Experimentally naïve young adult male Lister hooded rats Charles River UK) were used in all experiments. Rats were housed in groups of four prior to surgery and in individual cages post-surgery, under constant housing conditions (12 hours light:dark cycle with lights on at 07.00 hours, ambient temperature 21 ± 2˚C and relative humidity 55 ± 10%).
Food and water were freely available, and wet mash was provided for five days post-surgery.
The drug doses and behavioral schedule used were chosen to comply with the three (SB-258719) were purchased from Tocris Bioscience, Bristol, UK. 5-7-dihydroxytryptamine (5,7-DHT) creatine sulphate was purchased from Sigma Aldrich, Dorset, UK. Mephedrone, desipramine, WAY-100635, GR 127935 and SB-258719 were dissolved in 0.154M saline, and 6-OHDA and 5,7-DHT were dissolved in 0.2% w/v ascorbic acid. All doses are quoted as the salt.
Radiotelemetry
Radiotelemetry was conducted as previously described (Rodsiri et al., 2011 minute epochs and expressed as mean ± standard error of the mean (SEM) activity counts.
The change in body temperature (°C) from the baseline reading at 0 minute immediately prior to drug injection and the total cumulative activity counts in the 120 minutes following each injection were calculated and presented as mean ± SEM.
Microdialysis
As our Animals (Scientific Procedures) Act, 1986 project licence did not permit radiotelemetry and microdialysis to be performed in the same animal, microdialysis was measured in a separate cohort of rats using an identical protocol as previously described (Rodsiri et al., 2011 
Dopamine and 5-hydroxytrptamine depletion
In a third group of rats, bilateral i.c.v. injection of a monoamine neurotoxin (5,7-DHT or 6-OHDA) was performed under isoflurane anesthesia as previously described (King et al., 2009 ). All rats received desipramine (15mg/kg, i.p., 30 minute pre-treatment) to protect noradrenergic neurons prior to 5µl of 0.2% w/v ascorbic acid vehicle, 75µg/5µl of 5,7-DHT or 150µg/5µl of 6-OHDA into each lateral ventricle anterior-posterior -0.8, medial-lateral ±1.5, dorsal-ventral -3.8 from Bregma (Paxinos and Watson, 1997) at a rate of 5µl/minute.
These doses were chosen as they reportedly produce a similar degree of depletion (70-75% below control value; King et al, 2009; Nowak et al, 2009 ). Twenty-one days post-surgery, each rat (n=8 per treatment group) received three injections of saline vehicle (1ml/kg) or mephedrone (10mg/kg i.p.) at 2 hour intervals, with radiotelemetry measurements as described previously. Using a cross-over design, rats received the opposite treatment during repeat monitoring 28 days post-surgery to minimize inter-individual responses to drug treatment or the lesion.
Neurochemical detection by high performance liquid chromatography-electrical detection
Seven days after radiotelemetry recording (35 days after i.c.v. injection), rats were killed by concussion followed by immediate decapitation, and the hypothalamus, right striatum, frontal cortex and hippocampus were collected on a refrigerated table (4°C), flash frozen in liquid nitrogen and stored at -80°C until analysis of dopamine, 5-HT and their major metabolites by high performance liquid chromatography-electrical detection, as previously described (Shortall et al., 2013b) . Samples were thawed, weighed and sonicated for 30s in 800µl 0.05M perchloric acid containing 1µM sodium metabisulphite, centrifuged (17400xg, 4°C for 20min; Harrier 18/80: MSE Scientific Instruments, London, UK) and the supernatant filtered (0.45µM syringe tip filter, Kinesis Ltd, Saint Neots, UK). Monoamines were separated using a Targa C18 3µMVcolumn (100mm x 2.1mm; Phenomenex, Cheshire, UK) and detected using an Antec VT-03 cell with a glassy carbon 2mm working electrode set to +0.59V with an in situ Ag/AgCl ISAAC reference electrode. This system was also used to quantify extracellular dopamine and 5-HT in microdialysis samples. In addition, noradrenaline levels were measured in the same regions in 5,7-DHT and 6-OHDA pre-treated rats using a modified HPLC protocol (a mobile phase of 20mM KH 2 PO 4 /Na acetate, 8mM KCl, 0.1mM EDTA, 1mM OSA, containing 10% methanol, pH 4.07).
Effect of 5-HT 1A , 5-HT 1B and 5-HT 7 receptor antagonists on mephedrone-induced hyperactivity and hypothermia following a single injection
Locomotor activity (LMA) and rectal temperature were recorded from separate groups to establish the role of specific 5-HT receptors in acute mephedrone-induced hyperactivity and hypothermia, using previously described methods (Shortall et al., 2013a; Shortall et al., 2013b) . Rats (n=8 per treatment group) received saline vehicle (1ml/kg, i.p.), the 5-HT 1A
receptor antagonist WAY-100635 (0.5mg/kg), the 5-HT 1B receptor antagonist GR 127935 (3mg/kg) or the 5-HT 7 receptor antagonist SB-258719 (10mg/kg), followed 30 minutes later by vehicle (1ml/kg, i.p.) or mephedrone (10mg/kg). Doses of 5-HT receptor antagonists were selected from previous studies (Fletcher et al., 2002; Graf et al., 2004; Guscott et al., 2003; Rusyniak et al., 2007) .
Locomotor activity
Rats were placed in individual Perspex arenas and allowed to habituate for 60 minutes prior to the first injection. LMA was continuously recorded (in 5 minute time bins) for 30 minutes after the first and 60 minutes after the second injection using a Photobeam Activity System (San Diego Instruments, CA, USA) to record ambulation and rears.
Rectal temperature
In acute drug studies, rats were placed in individual Perspex arenas and basal temperature measured 40 minutes prior to the first injection to allow habituation to the recording procedure, which involved insertion of a rectal probe (Portec Instrumentation, Bedfordshire, UK) to a depth of 6.5cm for approximately 20 seconds. Rectal temperature was measured immediately prior to each injection and then at 20 minute intervals for the next 2 hours.
Statistical Analysis
Analyses were performed using GraphPad Prism v6.02 or SPSS v21 software. 
Results
Effects of repeated mephedrone on locomotor activity, body temperature and in vivo striatal dopamine release
Locomotor activity Mephedrone increased activity above vehicle control levels for 40 minutes after the first injection and 80 minutes after the second and third injections, such that there was a drug x time interaction (F (18,144) =3.43, P<0.001, Fig. 1a) . The response to vehicle appeared to diminish with each consecutive administration, whereas the magnitude of the mephedroneinduced increase was similar after each injection.
Analysis of total cumulative activity in the 2 hours following each injection confirmed that mephedrone caused a reproducible hyperactivity on each occasion, with no significant difference between injections (First: 580±56; Second: 567±98; Third: 416±115 counts/2 hours). The peak response (increase compared with each pre-injection value) was also similar (7.2 ± 2.2; 8.2 ± 3.3; 7.9 ± 2.7). However, in vehicle-treated rats, the total decreased from 197±105 following the first to 61±15 after the third administration (P<0.05), suggesting some habituation to injection, which was not observed following mephedrone. This was reflected by a drug x injection number interaction (F (2,16) =3.87, P<0.05), which was attributed to the change in the vehicle rather than mephedrone response.
Core body temperature
There were no between-group differences in temperature (recorded simultaneously with locomotor activity) in the 60 minutes prior to injection (data not shown), with baseline values (at the time of the first injection) being 37.8 ± 0.2°C in rats due to receive vehicle and 37.9 ± 0.1°C in those due to receive mephedrone. In vivo striatal dopamine and 5-hydroxydopamine efflux
In a separate group of rats to those used for radiotelemetry, there were no between-group differences in basal extracellular dopamine levels in the 60 minutes prior to the first injection (7.32 ± 1.65pmol/ml in rats due to receive vehicle and 5.08 ± 0.85pmol/ml in those due to receive mephedrone). Following injection, there was a drug x time interaction (F (18,319) =3.55,
P<0
.001, Fig. 1c ). Mephedrone rapidly increased extracellular dopamine levels above vehicle control for 40 minutes after the first and third injections and 60 minutes after the second, but dopamine levels returned to near basal between injections. Thus, each injection produced a similar magnitude (First: 298%; Second: 520%; Third: 435% peak change from baseline) and time course of elevation in extracellular striatal dopamine.
Basal extracellular levels of 5-HT were close to the detection limit but equivalent in both groups when measured immediately prior to the first injection (0.295 ± 0.12 and 0.323 ± 0.07pmol/ml in control and mephedrone groups, respectively). In vehicle-treated rats, postinjection 5-HT levels remained either close to or below the detection limit, and the preinjection value has been used to calculate the percentage increase (Fig. 1d) 
Ex vivo monoamine content
There was no significant effect of repeated mephedrone administration on tissue levels of dopamine, 5-HT or their major metabolites in the hypothalamus, striatum, hippocampus or frontal cortex measured 7 days after radiotelemetry recording (data not shown).
Effects of 5-HT or dopamine depletion on repeated mephedrone-induced changes in
locomotor activity and core body temperature
Locomotor activity
The third experiment again found that mephedrone caused a rapid increase in locomotor activity, which returned to basal levels between injections, whereas vehicle produced only a Consistent with the previous experiment, total cumulative activity in the 2 hours following each injection confirmed mephedrone-induced hyperactivity, with a drug x injection number interaction (F (2,36) =5.31, P<0.01, Table 1 ). 5,7-DHT completely prevented the response to the first mephedrone injection and attenuated that to the third (P<0.01versus
sham control mephedrone response). In contrast, 6-OHDA-treated rats continued to exhibit an increase in cumulative activity following each mephedrone injection which did not differ from the response in mephedrone-treated sham controls.
Core body temperature
Basal core body temperatures prior to the first injection on each test day (recorded simultaneously with locomotor activity in the same sham and lesioned rats) were equivalent, being 37.2 ± 0.2 and 37.5 ± 0.2°C in sham controls, 36.9 ± 0.2 and 37.2 ± 0.2°C in 5,7-DHT and, 37.5 ± 0.2 and 37.4 ± 0.2°C in 6-OHDA rats prior to injection of vehicle or mephedrone, respectively. The maximum temperature change from baseline following each mephedrone injection in sham controls (-1.2, -1.2 and -1.0°C following the first, second and third injections, respectively) was equivalent, but in agreement with the first study, the maximum temperature decrease (compared with pre-injection value) was attenuated following both the second and third (P<0.05) compared with the first injection (First: -1.2 ± 0.2°C; Second: -0.3 ± 0.1°C; Third: -0.1 ± 0.2°C).
There was a main drug x 5,7-DHT x time interaction (F (18,504) =1.72, P<0.05; Fig.   2c ,d) such that mephedrone significantly reduced core body temperature in sham controls 20-80 minutes after the first, 20-60 minutes after the second and at 40 and 80 minutes after the third injection. 5,7-DHT pre-treatment completely abolished mephedrone-induced hypothermia, and there was no difference between vehicle and mephedrone-treated 5,7-DHT rats at any time point, and the temperature change in 5,7-DHT mephedrone-treated rats was significantly attenuated compared to mephedrone-treated sham controls. There was also a main drug x 6-OHDA x time interaction (F (18,504) =1.76, P<0.05), such that mephedrone-induced hypothermia was reduced in 6-OHDA pre-treated rats where the decrease in temperature was only significant from sham controls at 40-80 minutes and at 40 minutes following the first and second injections, respectively.
Ex vivo neurochemistry
Dopamine, 5-HT and noradrenaline levels in the hypothalamus, right frontal cortex, hippocampus and striatum were measured 35 days after neurotoxin administration to confirm selective monoamine depletion. As expected the serotonergic neurotoxin, 5,7-DHT, significantly reduced 5-HT to 46% of control in the frontal cortex (P<0.001), 13% in the hippocampus (P<0.01), 42% in the hypothalamus (P<0.001) and 66% in the striatum although the latter did not reach significance due to high individual variation (Table 2) . In contrast, 6-OHDA reduced dopamine to 52% of control in the striatum (P<0.001) and 56%, 80% and 86% of control in the frontal cortex, hippocampus and hypothalamus, respectively, although the depletion in these areas was not statistically significant (Table 2) . However, the 6-OHDA-induced decrease in striatal dopamine was accompanied by a significant reduction in hippocampal 5-HT (F (2,20) =7.19, P<0.01) as well as decreased noradrenaline levels in the hypothalamus and hippocampus (F (2,21) =9.53, P<0.001), but noradrenaline levels were unchanged in the other regions examined.
Effect of 5-HT 1A , 5-HT 1B and 5-HT 7 receptor antagonists on acute mephedrone-induced hyperactivity and decreases in rectal temperature
In a final study, separate groups of rats were pre-treated i.p. with the 5-HT 1A receptor antagonist, WAY-100635, the 5-HT 1B receptor antagonist, GR 127935, or the 5-HT 7 receptor antagonist, SB-258719 to investigate the role of specific 5-HT receptors in mephedroneinduced hyperactivity and hypothermia.
Locomotor activity
None of the three 5-HT receptor antagonists had any effect on activity counts following their injection (data not shown). The predominant locomotor stimulant effect of mephedrone in vehicle pre-treated rats was a prolonged increase in ambulatory activity (p<0.05-0.001, accompanied by a smaller increase in fine movement without increased rearing consistent with previous studies by our group (Shortall et al., 2013b) and the current telemetry data. It was briefly attenuated WAY-100653 (Fig. 3a) at 15 minutes post-injection and more substantially attenuated by GR 127935 (Fig. 3b) Rectal temperature Injection of vehicle had no effect on rectal temperature irrespective of whether rats were pretreated with WAY-100635 (Fig. 4a) , GR 127935 (Fig. 4b) or SB-258719 (Fig. 4c ).
Mephedrone caused a transient but significant decrease in rectal temperature at 20 minutes (P<0.001) and 40 minutes (P<0.05) post-injection compared with vehicle, which was consistent with the duration and magnitude observed in a previous study by our group (Shortall et al., 2013a) . There was a WAY-100635 x mephedrone x time interaction (F (7, 196) =2.84, P<0.01, Fig. 4a ), such that the mephedrone-induced hypothermia was partially blocked by WAY-100635 from 20-40 minutes post-mephedrone. However, there was no significant GR 127935 x mephedrone x time interaction (F (7, 196) =1.16, P>0.05, Fig. 4b ) nor a SB-258719 x mephedrone x time interaction (F (7, 196) =1.35, P>0.05, Fig. 4c ).
Discussion
This study investigated the effects of repeated mephedrone injection on core body temperature, locomotor activity and striatal dopamine and 5-HT release in the rat, and examined the role of dopamine and 5-HT containing neurons on mephedrone-induced changes in body temperature and activity. This is one of only a few studies to use radiotelemetry to obtain a high temporal resolution of changes appropriate for the shortduration responses (Aarde et al., 2013; Miller et al., 2012; Wright et al., 2012) . The main findings were as follows; (1) while hyperactivity and increase in extracellular striatal dopamine seen after the first mephedrone injection were similar in magnitude and time course to those seen following the second and third injections, the hypothermia was attenuated with repeated dosing; (2) extracellular striatal 5-HT overflow was more variable but was enhanced when second and third injections were given when compared with the first response; (3) 6-OHDA did not affect hyperactivity but reduced the duration of the hypothermic response; (4) 5,7-DHT administration and 5-HT 1B receptor antagonism attenuated mephedrone-induced hyperactivity; (5) 5,7-DHT administration completely abolished, and 5-HT 1A receptor antagonism attenuated mephedrone-induced hypothermia.
Importantly, some of these observed effects contrast with those reported with MDMA, suggesting differing possible adverse effects following recreational use.
Mephedrone has a high affinity for rat dopamine and 5-HT transporters as well as the 5-HT 2A and 5-HT 2C receptors, and α 1A -and α 2A -adrenoceptors (Eshleman et al., 2013; Martinez-Clemente et al., 2012; Simmler et al., 2013) . It increases extracellular dopamine and to an even greater extent 5-HT in the nucleus accumbens (Baumann et al., 2012; Eshleman et al., 2013; Kehr et al., 2011; Wright et al., 2012) . The current study, in contrast, suggests that in the striatum, the percentage increase in 5-HT and dopamine is rather similar, at least after the second and third injections.
The repeated dose given in the current study (10mg/kg) did not produce any neurotoxic loss of brain regional dopamine or 5-HT measured 7 days post-injection. This is in marked contrast to MDMA, where a repeated dose schedule that releases striatal dopamine also produces significant long-term neurotoxic 5-HT depletion in the rodent (Green et al., 2003) , but similar to methcathinone where a much larger dose than that needed to elicit behavioral changes is required to obtain neurotoxicity (Sparago et al., 1996) . Although hypothermia protects against MDMA neurotoxicity (Malberg and Seiden, 1998 ), a previous study in which mephedrone produced hyperthermia in the rat also failed to detect any neurotoxic loss of post-mortem brain monoamines two weeks after a repeated dosing schedule similar to that used in the current study (Baumann et al., 2012) . These data therefore suggest that rapid repeated mephedrone administration is less likely to produce monoamine neurotoxicity than MDMA.
Mephedrone induces hyperactivity in rodents following both acute and intermittent administration (Angoa-Perez et al., 2012; Baumann et al., 2012; Kehr et al., 2011; Marusich et al., 2012; Shortall et al., 2013b; Wright et al., 2012) . Mephedrone (0.5 to 30 mg/kg i.p. or subcutaneous) has consistently been shown to elicit hyperactivity in a variety of rat strains, when given during both the light (Gregg et al., 2013; Lisek et al., 2012; Shortall et al., 2013b) or dark (Miller et al., 2013; Motbey et al., 2012) phase of the circadian cycle. Because significant hyperactivity was found irrespective of circadian phase, the current study was conducted in the light phase to enable comparison with the many studies on MDMA, including our own, which use this protocol. In the current study, repeated 'binge-style' mephedrone administration caused reproducible hyperactivity after each injection, the onset of which occurred within minutes of injection but returned to baseline levels within 1 hour.
The time courses for both the striatal dopamine release and the hypothermia are consistent with a previous study using a single systemic injection (Shortall et al., 2013b) . It is noteworthy that the peak plasma level of mephedrone in the rat follows a similar temporal pattern following subcutaneous injection (Miller et al., 2013) . Importantly, the total ambulatory activity counts following the second and third injections of mephedrone were comparable to those following the first injection. This response therefore differs markedly from MDMA where progressively increasing hyperactivity was observed following a similar repeated dosing schedule (Rodsiri et al., 2011 ).
In the current study, central 5-7-DHT administration markedly attenuated the hyperactivity observed following mephedrone injection 21 or 28 days later, while i.c.v.
injection of 6-OHDA had no effect on mephedrone-induced hyperactivity. This observation is consistent with the ability of pCPA-induced 5-HT depletion to reduce mephedrone-induced hyperactivity in mice (Lopez-Arnau et al., 2012) and supports a key role for 5-HT in mephedrone-induced hyperactivity. In the current study blockade of 5-HT 1B , and to a lesser extent 5-HT 1A (but not 5-HT 7 ), receptors also reduced mephedrone-induced hyperactivity, and this is consistent with similar observations on MDMA-induced hyperactivity (Fletcher et al., 2002; McCreary et al., 1999) . The affinity of mephedrone for the 5-HT 1B receptor has not yet been investigated and so it is difficult to ascertain whether this effect on mephedroneinduced hyperactivity is due to a direct effect on this receptor.
Although hyperthermia has not been recorded in mephedrone users, there is evidence that it alters peripheral thermoregulation because reported adverse effects include cold/blue fingers, hot flushes and sweating (Winstock et al., 2011; Wood and Dargan, 2012) which may occur from peripheral changes in blood flow. Earlier studies have generally failed to observe hyperthermia in rodents given an acute injection of mephedrone, even when the animals are group-housed or kept in raised ambient temperature (Shortall et al., 2013a; Wright et al., 2012) . However, hyperthermia was observed in two studies investigating the effects of repeated mephedrone injection (Baumann et al., 2012; Hadlock et al., 2011) . Of note, both of these studies used Sprague Dawley rats and subcutaneous injections so there could be strain and/or pharmacokinetic differences (Wright et al., 2012) . These repeated injection studies also used a rectal probe to measure the response at 1 hour intervals so the observed hyperthermia may have resulted from an additive effect of repeated mephedrone injection combined with stress-induced hyperthermia associated with rectal measurement as evident in vehicle control animals (Baumann et al., 2012; Hadlock et al., 2011) . The current study therefore used radiotelemetry to measure the temperature response following repeated mephedrone injection and showed it produced hypothermia as reported following a single injection (Aarde et al., 2013; Miller et al., 2012 ). In the current study, 5,7-DHT administration abolished the hypothermic response to mephedrone. Furthermore, administration of the 5-HT 1A receptor antagonist, WAY-100635, attenuated mephedroneinduced hypothermia while antagonism of the 5-HT 1B or 5-HT 7 receptors had no effect.
Although 5-HT 1A receptors are implicated in the hypothermic response, their involvement is almost certainly a consequence of 5-HT release and/or inhibition of reuptake, because the low affinity of mephedrone for the 5-HT 1A receptor (Ki>20μM; Simmler et al, 2013 ) makes any direct effect unlikely. Interestingly, pre-treatment with WAY-100635 at the same dose as used herein also prevents the hypothermic response to MDMA (Rusyniak et al., 2007) but the involvement of 5-HT 1B and 5-HT 7 receptors in the thermoregulatory effect of MDMA has not been documented. In contrast, mephedrone injection to 6-OHDA-treated rats produced a hypothermic response which was shorter in duration than that seen in sham controls. At first, this appears paradoxical because we have shown that administration of the dopamine D 1 receptor antagonist, SCH 23390, prolonged mephedrone-induced hypothermia (Shortall et al., 2013a) . However, the limited depletion of dopamine in the hypothalamus makes it difficult to come to any firm conclusion about the role of dopamine in mephedrone-induced hypothermia.
Tolerance to the hypothermic effect of mephedrone is intriguing and is unlikely to be due to a pharmacokinetic effect as locomotor and dopamine responses were unaffected.
Considerable evidence shows that 5-HT plays a major role in thermoregulation, particularly when body temperature is perturbed by amphetamine-like drugs (Docherty and Green, 2010) .
However, it is unclear whether increased 5-HT release with repeated dosing, observed herein, is associated with tolerance to the hypothermic effect of mephedrone. Although the limited depletion of hypothalamic dopamine makes it impossible to completely exclude a role of this monoamine in mephedrone-induced hypothermia the fact that this response is unaffected by dopamine D 2 receptor blockade and prolonged by D 1 receptor antagonism (Shortall et al., 2013a) suggests that mephedrone-induced increases in dopamine efflux are unlikely to contribute to the drug-induced hypothermia. In contrast, modulation of central serotonergic neurotransmission plays a key role in mediating both the hyperlocomotor and hypothermic effects of mephedrone.
Although caution is required in attempting to translate the relevance of these findings in the rat to those in man, they demonstrate the need to evaluate the pharmacology and psychoactive effects of any new amphetamine analogues and not rely on prediction from structural analogy.
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